TSX:7011 29 June 2025 - 5 January 2026

April 28, 2026, 10:58 PM EDT. Mesoblast (ASX:MSB) shares closed at A$2.15, down 6.5% over the past week despite a 0.5% gain in the last day. The biopharma firm shows mixed signals: positive 1- and 3-year shareholder returns contrast with weaker short-term performance. Analysts highlight Mesoblast as 43.9% undervalued with a fair value target of A$3.83, driven by heart failure drug rexlemestrocel L, pending potential U.S. accelerated FDA approval. However, risks loom from slow Ryoncil sales and trial delays. Valuation models conflict; discounted cash flow suggests undervaluation at A$3.05, but a high price-to-sales ratio of 30.5x versus industry norms raises questions if the market overpays for growth or if assumptions are overstretched. Investors remain cautious amid uncertain future earnings and regulatory hurdles.